## Clinical Diagnosis: Chronic Cavitary Aspergillosis This presentation is highly suggestive of **chronic pulmonary aspergillosis (CPA)**: - Cavitary lesion in upper lobe (typical site) - Air-crescent sign (pathognomonic for aspergilloma) - Risk factors: COPD, chronic corticosteroid use, cavitary lung disease - Hemoptysis (from erosion into pulmonary vessels) - Negative AFB smear (excludes tuberculosis) **Key Point:** The air-crescent sign is the hallmark radiologic finding of aspergilloma — a fungal ball within a pre-existing cavity. ## Why Sputum Culture + Itraconazole Immediately? **High-Yield:** In chronic cavitary aspergillosis: 1. **Sputum culture is diagnostic** — Aspergillus fumigatus grows readily from sputum in CPA 2. **Itraconazole is first-line** for chronic pulmonary aspergillosis (not voriconazole) 3. **Do NOT wait for culture results** — clinical suspicion is high enough to start therapy 4. **Itraconazole achieves excellent lung penetration** and is oral, allowing outpatient management **Clinical Pearl:** Aspergillus serology (IgG antibodies) and galactomannan antigen may support diagnosis, but sputum culture remains the gold standard. **Mnemonic: CAVITARY ASPERGILLOSIS** — **C**avity + **A**ir-crescent + **V**oriconazole/Itraconazole + **I**mmunocompromised (steroids) + **T**reatment immediate + **A**spergillus fumigatus + **R**isk factors + **Y**earning for antifungal ## Why Not the Other Options? | Option | Why Wrong | |--------|----------| | HRCT + culture, then voriconazole | Voriconazole is for invasive aspergillosis, not chronic cavitary disease. Itraconazole is preferred for CPA. Delaying therapy while awaiting culture is unnecessary. | | Anti-TB therapy | AFB smear is negative; TB is unlikely. Starting TB drugs delays effective antifungal therapy and exposes patient to unnecessary toxicity. | | Bronchoscopy + defer therapy | BAL is not diagnostic for aspergilloma (fungal ball in cavity is not easily sampled by BAL). Deferring therapy allows disease progression and risk of massive hemoptysis. | ## Treatment Algorithm for Chronic Cavitary Aspergillosis ```mermaid flowchart TD A[Cavitary lung lesion + air-crescent sign + hemoptysis]:::outcome --> B{Clinical suspicion for aspergilloma?}:::decision B -->|High| C[Obtain sputum for culture & Aspergillus serology]:::action C --> D[Start itraconazole 200 mg BD immediately]:::action D --> E[Monitor clinical response & repeat imaging at 3 months]:::action E --> F{Improvement?}:::decision F -->|Yes| G[Continue itraconazole for 6-12 months]:::action F -->|No| H[Consider voriconazole or surgical resection]:::action I[Massive hemoptysis during treatment?]:::urgent --> J[Bronchial artery embolization or surgery]:::action ``` ## Key Management Points **Key Point:** Duration of itraconazole is typically 6–12 months, with imaging follow-up at 3 months to assess response. **Warning:** Do NOT confuse chronic cavitary aspergillosis with invasive aspergillosis (which occurs in severely immunocompromised patients and requires voriconazole or liposomal amphotericin B). **Clinical Pearl:** Massive hemoptysis is a life-threatening complication; bronchial artery embolization or surgical resection may be needed if antifungal therapy fails. [cite:Harrison 21e Ch 200; Park 26e Ch 6]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.